Pilot Study of Neoadjuvant/Adjuvant Cemiplimab for High Risk Cutaneous Squamous Cell Carcinoma
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Cemiplimab (Primary)
- Indications Head and neck cancer; Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 08 Jun 2021 Trial design, presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 29 Jun 2020 Status changed from active, no longer recruiting to recruiting.
- 15 Jun 2020 New trial record